Celcuity (CELC) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Celcuity is a clinical-stage biotech focused on developing targeted therapies for cancers driven by the PAM pathway. Its strategic pivot from diagnostics to therapeutics is centered on the late-stage development of gedatolisib, a highly differentiated dual inhibitor. Recent Phase 3 data in HR+/HER2- advanced breast cancer suggests practice-changing potential, positioning the company for a pivotal transition to commercialization if successful.

OncologyBreast CancerProstate Cancer

Technology Platform

Pharmacological platform centered on gedatolisib, a single-molecule, dual pan-PI3K and mTORC1/2 inhibitor designed for comprehensive blockade of the PAM (PI3K/AKT/mTOR) pathway to overcome resistance mechanisms common with single-target agents.

Opportunities

Gedatolisib has practice-changing potential in the large HR+/HER2- advanced breast cancer market, particularly for the PIK3CA wild-type population with limited targeted options.

A second major opportunity exists in biomarker-defined (PTEN-loss) metastatic prostate cancer, another area of high unmet need.

Risk Factors

The company faces significant clinical and regulatory risk as it moves toward submission, substantial execution risk in building a commercial organization, and high concentration risk with its value tied to a single asset.

Future capital needs may lead to dilution.

Competitive Landscape

Competes against approved PI3Kα, AKT, and mTORC1 inhibitors in breast cancer, differentiated by gedatolisib's comprehensive pan-PI3K/mTORC1/2 inhibition in one molecule. Must establish superiority in efficacy/tolerability to gain market share in a crowded, evolving landscape.

More companies in Diagnostics & Precision Medicine →More companies in United States →